Healthspan Weekly — Mar 10, 2026
Photo: lyceumnews.com
Week of March 10, 2026
The Big Picture
Two things happened this week that, taken together, tell you where this field is actually headed: scientists built a biological aging clock that finally stitches together proteins, metabolites, and DNA methylation into one score that predicts death better than anything before it — and a completely separate study showed that the difficult person in your life is measurably accelerating your epigenetic aging. Better measurement and harder-to-ignore evidence that the "soft" stuff is biology. That's the week.
This Week's Stories
Your Biological Age Just Got a Much Better Measuring Stick
![Lab team analyzing blood and DNA samples — CDC scientist transfers H7N9 / Photo Credit: James Gathany
The problem with biological age clocks has always been fragmentation. One measures chemical tags on your DNA. Another reads proteins in your blood. A third tracks metabolites. They don't always agree, and none was trained on enough real health data to be truly useful in a clinic.
A new paper in Nature Aging introduces OMICmAge, and it takes a different approach. Built from roughly 31,000 electronic health records in the study dataset, it integrates proteomic and metabolomic information through epigenetic proxies — essentially using multiple biological data streams to train a single DNA-methylation score. The result predicts mortality at least as well as, and often better than, existing clocks.
What makes this more than incremental: rather than forcing you to choose between proteomics or epigenomics, OMICmAge reconciles them. Different organs age at different speeds — your liver clock and your brain clock can diverge sharply — and tools like this are steps toward capturing that complexity in something a clinician can actually act on.
The near-term question is adoption. If commercial platforms like TruDiagnostic integrate multi-omic methodology, and if ARPA-H's new healthspan trial platforms (more on that below) standardize which clocks get used in large studies, OMICmAge or its successors could become the default readout for whether an intervention is actually working. Meanwhile, clinics are already using pace-of-aging clocks like DunedinPACE for shorter-term feedback — a complementary tool that responds to lifestyle tweaks within months. Two clocks, two timescales, one goal.
The People Draining Your Life Are Also Aging Your Cells
You already know this person. The family member who leaves you hollowed out. The colleague who manufactures emergencies. The friend who takes and takes. New research puts molecular numbers behind what your nervous system has been telling you.
A study covered by The Washington Post this week found that "hasslers" — the researchers' term for chronically difficult people in your social network — are associated with elevated epigenetic markers of accelerated aging. Nearly 30 percent of people in the study sample had at least one. Researchers suggest stress physiology may be involved: chronic interpersonal friction was associated with elevated cortisol and inflammatory signals, which are linked to epigenetic changes that aging clocks detect.
This isn't soft wellness advice. In this study, who you spend time with was associated with accelerated cellular aging signals.
The corollary matters just as much: high-quality social connection appears protective. A University of Kansas study published this week found that counties with stronger civic engagement show better aggregate health outcomes — though the gains aren't equitably distributed across racial groups. And longitudinal work continues to show that midlife relationships powerfully predict late-life thriving, echoing the Harvard 85-year studies and Blue Zones research.
The practical question this raises and doesn't yet answer: is creating distance from a hassler as powerful as adding more positive connection? Worth tracking.
A Gerozyme Injection Regrew Knee Cartilage in Mice. Here's What That Actually Means.
Source: news.stanford.edu
This study published in Science late last year, but it's having its viral moment now — 400 points on Hacker News this week — so let's be precise about what it does and doesn't show, because most headlines got it wrong.
Stanford researchers identified a protein called 15-PGDH that, in their data, increases with age by about twofold. They're calling it a "gerozyme" — an enzyme of aging — and it appears to suppress the regenerative capacity of cartilage-producing cells in joints. When they injected an inhibitor into old mice, cartilage regrew. Critically, the chondrocytes (cartilage cells) shifted their gene expression to a more youthful state without any stem cell involvement. That's mechanistically novel: it's not adding new cells, it's reprogramming the ones already there.
Human knee tissue collected during joint replacement surgeries also responded — samples began forming new, functional cartilage. A pill-based version is in early clinical trials for age-related muscle weakness.
Now the honest calibration: the preliminary Phase I human trial underway focuses on safety, not efficacy. No human trial has begun testing cartilage regeneration specifically. Additional animal model coverage this week — including rabbit early-damage models — helps explain the media spike but doesn't change the evidence tier. This is a genuinely exciting mechanistic finding, not a treatment. The bigger idea — that specific proteins accumulate with age and suppress tissue function, and that blocking them can restore it — is the concept worth watching.
ARPA-H Is Quietly Building the Infrastructure That Could Change Everything
If you've ever wished someone would just run a proper, large-scale trial to find out whether a longevity drug actually adds healthy years, the U.S. government nudged that future closer. ARPA-H announced up to $144 million in funding for projects aimed explicitly at extending healthspan — not treating single diseases.
The money isn't going to one moonshot. It's seeding platforms: multi-site clinical networks, standardized biomarkers (including epigenetic clocks like DunedinPACE), and modeling tools that simulate how slowing biological aging would impact frailty, healthcare costs, and independence over decades.
Separately, the Buck Institute launched Healthspan Horizons this week — a data platform designed to aggregate wearables, labs, clinical notes, and long-term outcomes into an AI-ready system for population-scale discovery. If ARPA-H builds the trial networks and Buck provides the observational baseline, the gap between "promising mouse study" and "we know this works in humans" could shrink dramatically.
For you, this is the infrastructure layer. It means future rapamycin, senolytic, or combination trials can be bigger, faster, and measured by outcomes that matter — walking speed, independence, time to first major disease — instead of just single biomarkers. The next thing to watch: which specific interventions get slotted into these platforms.
Why Keeping Older Workers Is Actually a Longevity Strategy — for Everyone
This landed on Hacker News with nearly 300 points, and it sits at the exact intersection of purpose science and aging biology that rarely gets covered well.
Stanford's Center on Longevity makes the case that purposeful engagement in later life isn't just good for morale — it's one of the most underestimated biological levers we have. Continued work, whether full-time, part-time, or project-based, is associated with better cognitive resilience, cardiovascular health, and overall longevity. Mental and social challenges stimulate brain metabolism and neuroplasticity the way exercise trains muscles. People with strong purpose scores show lower chronic inflammation and reduced risk of early death.
A Yale analysis reinforces this from a different angle: people with more positive expectations about aging were likelier to gain physical or cognitive function over a decade, not just decline more slowly. Beliefs about aging predict real biological outcomes.
Purpose isn't a luxury you earn after the health work is done. It may be part of the health work itself. The practical question for any reader: what does continued purposeful engagement look like for your next decade?
⚡ What Most People Missed
Your gut microbiome may be a brain-aging dial you can turn. Researchers depleted the gut microbiome of old mice with antibiotics and saw broad rejuvenation signals in the brain — better blood vessel density, more myelination, calmer immune cells. Blocking a single inflammatory factor, eotaxin-1, reproduced several benefits, giving pharma a specific target. Mouse work, not a protocol — but it sharpens the case that gut-driven inflammation is one of the most adjustable knobs on brain aging.
Senolytics and exercise may work the same lever. A new review in The Journal of Physiology argues that senolytic drugs and training protocols push aging muscle in the same rejuvenating direction — clearing senescent cells and restoring stem cell function. The interesting idea: pulse a senolytic around periods of intense training to clear damaged cells, then let exercise-driven rebuilding dominate. Still preclinical and speculative, but seeing exercise framed as a "natural senolytic" by mainstream physiologists is a notable shift.
Fat cells remember being obese — even after you lose the weight. A Nature paper showed that adipose tissue retains epigenetic signatures of prior obesity after substantial weight loss, predicting faster regain. Directly relevant to the GLP-1 era: drugs that produce rapid weight loss may not erase the cellular wiring that predisposes to regain. Maintenance strategies — and possibly targeted tissue-reprogramming interventions — will be central to durable metabolic health.
A blood test may predict dementia 25 years out — starting with women. New data suggest p-tau217 levels in blood can identify women at elevated Alzheimer's risk decades before symptoms. A complementary Nature Medicine paper provides prospective prediction data. If both lines hold, midlife screening becomes far more actionable — and the question shifts from "can we detect it?" to "what do we do with the information?"
GLP-1 drug switching keeps people in the game longer — in the study sample. A JAMA Network Open study found that adults who switched between GLP-1 medications were more likely to remain on therapy longer in the study sample than those who did not — reframing these drugs as a modifiable, long-term regimen rather than a one-shot choice. Separately, new kidney data suggest GLP-1s may protect renal function beyond their metabolic effects.
📅 What to Watch
- If ARPA-H publishes which interventions it will fund first, it reveals whether the U.S. government's biggest healthspan bet favors rapalogs, senolytics, lifestyle packages, or combinations — and sets the research agenda for a decade.
- If an independent lab replicates Stanford's 15-PGDH gerozyme results in a second animal model, the human clinical timeline becomes worth taking seriously; without replication, it remains a beautiful finding looking for confirmation.
- If Buck's Healthspan Horizons enrolls 10,000 participants quickly, it means real-time population benchmarks for VO2, sleep, and strength by summer — and a practical way clinics can tell you where you actually stand.
- If the p-tau217 dementia biomarker study releases full sensitivity and specificity data, it will clarify whether midlife Alzheimer's screening for women is on a 5-year or 15-year horizon — a distinction that changes everything about prevention planning.
- If rapamycin human longevity trial interim data confirm mouse healthspan gains at low intermittent doses, the "cheapest longevity drug" conversation would move toward clinical prescribing and guideline consideration.
A gerozyme that makes old cartilage cells forget they're old. A clock that reads your proteins, metabolites, and DNA at once and tells you how fast you're actually dying. A study confirming that your most exhausting relative is literally aging you at the cellular level — which, honestly, you already knew.
Science has now validated the Thanksgiving exit strategy as a longevity intervention. Your epigenome thanks you for leaving early.
Until next week. —Healthspan Weekly